Alzheimer’s patient who says he can’t remember killing his granddaughter sentenced to prison in Japan
An Alzheimer’s patient in Japan who says he cannot remember killing his granddaughter nearly two years ago has been sentenced to four and a half years in prison. Susumu Tomizawa, 88, got into an argument with his 16-year-old granddaughter, Tomomi, in their home in Fukui Prefecture on Sept. 9, 2020. On the same night, he took a 6.69-inch-long kitchen knife and went into her bedroom, where he repeatedly stabbed her in the neck.
news.yahoo.comCovid-19 could lead to cognitive decline, especially among older adults, new research suggests
Studies presented at an Alzheimer’s Association conference this week, not yet peer-reviewed, emphasize the need for vaccination, an association vice president said. “The best advice is don’t get covid.”
washingtonpost.comSanjay Gupta's prescription for fighting off dementia
Sanjay Gupta's prescription for fighting off dementia The neurosurgeon, CNN commentator and author of "Keep Sharp: Build a Better Brain at Any Age" has long studied the brain and the onset of Alzheimer's. He talks with CBS News chief medical correspondent Dr. Jon LaPook about the recommended steps to a healthier brain, from diet and exercise to the value of sleep and social interaction.
cbsnews.comFormer MLB pitcher with Alzheimer’s found safe near Astrodome area, police say
HOUSTON – A former Major League Baseball pitcher with Alzheimer’s has been found safe Thursday afternoon near the Astrodome area, police confirmed. Roric Harrison, 74, went missing on Wednesday off Main Street in the Texas Medical Center. Police said he was found by a good Samaritan and is safely back home with his family. Police said Harrison was a pitcher in Major League Baseball for five years back in the 1970s. Harrison, who was signed to the Houston Astros at a point in his career, was the last American League pitcher to hit a home run in an American League game before they introduced the designated hitter.
Biogen hits snag after Alzheimer's drug fails to win support from FDA panel
A Food and Drug Administration panel on Friday unexpectedly declined to endorse Biogen's experimental Alzheimer's drug aducanumab in a setback for the pharmaceutical company. In an 8-1 vote, the panel said Biogen's late-stage study didn't provide "strong evidence" showing that aducanumab effectively treated Alzheimer's. Alzheimer's disease is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills. The U.S. agency has approved Alzheimer's drugs aimed at helping symptoms, not actually reversing or slowing the disease itself. The FDA's final decision on Biogen's drug is expected by March.
cnbc.comBiogen's stock jumps 42% after FDA staff says it has enough data to support approving Alzheimer's drug
Biogen's stock jumped 42% in midmorning trading Wednesday after the Food and Drug Administration staff said they have enough data to support approval of the company's experimental Alzheimer's drug Aducanumab. "Based on the considerations above, the applicant has provided substantial evidence of effectiveness to support approval," FDA staff said in a document reviewing the drug published on the agency's website. The FDA also said the drug has "an acceptable safety profile that would support use in individuals with Alzheimer's disease." The FDA has approved Alzheimer's drugs aimed at helping symptoms, not actually reversing or slowing the disease itself. The FDA's final decision on Biogen's drug is expected by March.
cnbc.comUPDATE: 76-year-old woman with Alzheimer’s found
Update: Houston police located an elderly woman who had been reported missing Saturday. The Houston Police Department is searching for an elderly woman with Alzheimer’s reported missing in Houston. Gloria Saldana, 76, was last seen Friday leaving the 10100 block of Lost Trail St. in an unknown direction. Saldana is described as a Hispanic female weighing 104 pounds and standing 4′8′' tall with brown eyes and black and grey hair. Anyone with information on her whereabouts is urged to contact the Houston Police Patrol at (713) 884-3131 or the Houston Police Department Missing Persons Division at (832) 394-1840.
This is 'the most important decision' the FDA will make in 2020, says analyst
The Food and Drug Administration's call on whether to approve Biogen's experimental Alzheimer's drug, aducanumab, will be the "most important decision" the federal regulator will make in 2020, Bernstein analyst Ronny Gal said Friday. When asked if he thought the FDA would approve the drug, Gal said, "Yes." Biogen's drug targets a "sticky" compound in the brain known as beta-amyloid, which is hypothesized to play a role in the devastating disease. The FDA has approved Alzheimer's drugs aimed at helping symptoms, not actually reversing or slowing the disease itself. However, some analysts are skeptical of whether Biogen's drug actually works after the company's apparent reversal on exploring FDA approval.
cnbc.comExperts split sharply over experimental new Alzheimer's drug
But others were dubious.Changes made during the study and unusual analyses of the data made the results hard to interpret. "It's hard to know exactly what happened here," said Dr. Howard Fillit, chief science officer of the Alzheimer's Drug Discovery Foundation. "The drug "is worthy of significant, rigorous exploration" and review by the FDA, she said. John Ioannidis, a Stanford University expert on research methods, said patients' need should not drive the FDA's decision. "If we go down that path, we're likely to introduce a lot of ineffective treatments for diseases that are really common," he said.
abc13.comJudge's family in turmoil after her Alzheimer's diagnosis
HOUSTON, Texas (KTRK) -- Should a Court of Appeals Justice remain on the job after an Alzheimer's diagnosis?That is the question at the heart of a family saga involving the mayor of West University Place and his entire family.When you walk into the stately First Court of Appeals courthouse in downtown Houston, Justice Laura Higley's smiling face is displayed along with the other justices.At the city hall of West University Place, her husband Bob Higley's picture is also on display, as its current mayor.However, it's the court filings in Harris County Probate Court 2 that paints the picture behind the smiling images. "The sons also accuse their own father, Mayor Bob Higley, as having "acted as a malevolent enabler in that he has encouraged Justice Higley not to resign or retire from serving as Justice in the First Court of Appeals. ""He's the mayor of West University, but obviously the sons feel like he has not done what he's supposed to do," said McCandless. "She should not be in that position. She needs to have proper care, and it must be very difficult for those sons to say, 'We have to take action.
abc13.comFDA verdict on Biogen's Alzheimer's drug likely to be a 'political decision,' analyst says
Federal regulators may buckle to public and political pressure to approve Biogen's experimental Alzheimer's drug, aducanumab, Jefferies' Michael Yee told CNBC on Monday. Biogen's drug would be worth billions. Yee said regulators will likely face pleas from friends and family members of Alzheimer's patients asking for fast-track approval of the drug. But Yee, like many other analysts, is also skeptical of Biogen's new analysis of the drug. "We're more cautious on Biogen" and investors should be too, Yee said, claiming that Biogen's data on its drug is "murky."
cnbc.comCramer: This biotech stock could be worth over $100 billion on an FDA approval
Biotech firm Biogen could double its market cap on regulatory approval for its experimental Alzheimer's drug, aducanumab, CNBC's Jim Cramer said Wednesday. The FDA has approved Alzheimer's drugs aimed at helping symptoms, not actually reversing or slowing the disease itself. The stunning reversal from Biogen was initially met with deep skepticism from investors, but Cramer expects that will change. "I think they'll ultimately become believers because Biogen resumed work on this drug at the behest of the FDA," Cramer said. The stock has rallied 34% since it announced it was seeking approval for its Alzheimer's drug last week.
cnbc.comBiogen CEO 'reasonably confident' once-doomed Alzheimer's drug will be granted FDA approval
Biogen CEO Michel Vounatsos told CNBC on Wednesday that he is "reasonably confident" the U.S. Food and Drug Administration will approve the drugmaker's experimental Alzheimer's drug. "We worked in full transparency with the regulator," Vounatsos told "Squawk Box," emphasizing the FDA has all of the company's data on the drug. "This was a thorough engagement, and as CEO I'm reasonably confident this will lead to market approval one day." Shares of Biogen soared more than 26% on Tuesday after the drugmaker shocked investors by announcing it was seeking regulatory approval for its once failed Alzheimer's drug, aducanumab. Alzheimer's disease can cause people's memory and mind to deteriorate to the point where they cannot function on their own and eventually die.
cnbc.comBiogen to seek US approval for Alzheimer's drug, sending shares soaring 34%
Biogen on Tuesday made a surprising reversal on its Alzheimer's treatment with plans now to seek U.S. regulatory approval, after data from more patients in two discontinued studies showed that the drug improved cognition at high doses. The drugmaker's shares soared 37% in premarket trade, erasing most of their losses this year that came after it abandoned two studies for the drug. Biogen and partner Eisai Co Ltd had in March decided to end two late-stage trials of aducanumab based on a so-called "futility analysis" of data, which revealed the trials had little hope of succeeding. The failure of the treatment, which was widely expected to be Biogen's next blockbuster treatment, spurred demands on Wall Street for it to spend more on product acquisitions at a time when its peers have splurged on billions of dollars in deals. The company said more data became available after the two studies were discontinued in March, resulting in a larger dataset and a new analysis showed that one of the trials met the main goal, while the other did not.
cnbc.comUntangling the Facebook data scandal, Inside MIT's "Future Factory," For better or worse: Living with Alzheimer's
Untangling the Facebook data scandal, Inside MIT's "Future Factory," For better or worse: Living with Alzheimer's Lesley Stahl reports on Aleksandr Kogan, the link between Facebook and Cambridge Analytica; then, Scott Pelley goes inside MIT's "Future Factory"; and, for better or worse, living with Alzheimer's
cbsnews.comNew drug shows promise for helping Alzheimer's
New drug shows promise for helping Alzheimer's Researchers at Mount Sinai Hospital in New York are testing a new drug that they hope will slow the progression of Alzheimer's disease by protecting nerve cells in the brain. Alison Harmelin reports.
cbsnews.comSiblings swim English Channel for Alzheimer's awareness
Siblings swim English Channel for Alzheimer's awareness Devin, Dustin and Danielle Wahl could be the first trio of siblings to swim across the English Channel at the same time. They're doing it in part to raise awareness about Alzheimer's, a disease that affected their loved ones. Norah O'Donnell reports.
cbsnews.com